Novavax Inc (NVAX)

Drugs • Health Care

Stock AI

News & Reports

July 30, 2026 Novavax to Unveil Second Quarter 2026 Financial Results Novavax Inc. is set to announce its financial results for Q2 2026 on August 6, before U.S. market opening. A live conference call will follow to discuss the results and company updates.

June 01, 2026 Novavax Inc. to Showcase Innovations at the 2026 Jefferies Global Healthcare Conference Novavax, Inc. will showcase its innovations at the Jefferies Global Healthcare Conference on June 4, 2026. The event will include a fireside chat discussing the company's growth strategies and commitment to healthcare innovation.

May 07, 2026 Novavax Inc. Announces Participation in BofA Securities 2026 Health Care Conference Novavax, Inc. will participate in the BofA Securities 2026 Health Care Conference, engaging with investors through a fireside chat and meetings. The company aims to highlight its strategic innovations in vaccine development and commitment to addressing global health challenges.

May 06, 2026 Novavax Reports First Quarter 2026 Financial Results and Operational Highlights Novavax, Inc. (Nasdaq: NVAX) has unveiled its financial results and operational highlights for the first quarter of 2026, revealing both challenges and significant strategic advancements. The company continues to push forward with its corporate strategy, which emphasizes partnerships, capital-efficient research and development (R&D), and lean operational efficiency.

May 06, 2026 Novavax Inc. Reports Q1 2026 Financial Results: A Shift in Strategy Amidst Challenges Novavax Inc. faced a significant revenue decline in Q1 2026 due to changes in COVID-19 vaccine responsibilities. Despite challenges, the company focuses on strategic partnerships and an innovative product pipeline aimed at future growth.

April 29, 2026 Novavax Sets the Stage for Q1 2026 Financial Results Novavax, Inc. will announce its Q1 2026 financial results on May 6, 2026, at 8:30 a.m. ET. Investors can join the call to gain insights into the company's performance and future direction. A replay will be available for those unable to attend live.

March 30, 2026 Novavax Appoints Dr. Robert Walker as Head of Research & Development Novavax has appointed Dr. Robert Walker as Executive VP and Head of R&D, succeeding Dr. Ruxandra Draghia-Akli. With over 30 years in drug development, Dr. Walker aims to enhance Novavax's vaccine initiatives and address global health challenges.

February 26, 2026 Novavax Inc. Set to Engage Investors at Upcoming Conferences Novavax, Inc. will participate in three key investor conferences in March 2026 to discuss its vaccine technology and strategic initiatives. These events are critical for strengthening investor relationships and showcasing the company's advancements in healthcare solutions.

February 26, 2026 Novavax Inc. Reports Strong Financial Results and Strategic Advancements for 2025 Novavax, Inc. reported impressive financial performance for 2025, with a 67% revenue increase driven by Nuvaxovid sales. Strategic partnerships with Pfizer and Sanofi are set to enhance growth, while ongoing R&D investments position the company for future success.

February 26, 2026 Novavax Inc. Reports Robust Financial Performance in 2025 Annual Report Novavax Inc. reported a remarkable financial turnaround in 2025, achieving $1.1 billion in revenue and a net income of $440.3 million. Key partnerships, particularly with Pfizer and Sanofi, bolstered its growth, while cost management strategies improved operational efficiency. Looking ahead, Novavax is poised for further advancements in vaccine development.

February 19, 2026 Novavax Inc. Set to Announce Fourth Quarter and Full Year 2025 Financial Results Novavax Inc. is set to announce its fourth quarter and full year 2025 financial results on February 26, 2026. A conference call will follow the release, providing insights for investors and analysts.

January 20, 2026 Novavax and Pfizer Forge Strategic Partnership: A License Agreement on Matrix-M® Adjuvant Novavax has entered a strategic partnership with Pfizer, allowing the latter to use its Matrix-M® adjuvant technology. This deal promises substantial financial benefits for Novavax and positions both companies to enhance vaccine efficacy.

January 07, 2026 Novavax Inc. to Showcase Innovations at J.P. Morgan Healthcare Conference Novavax, Inc. will present its latest vaccine innovations at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company aims to showcase its advancements in vaccine technology and future projects, with a live webcast accessible for broader audience participation.

November 12, 2025 Novavax Inc. to Participate in Jefferies London Healthcare Conference Novavax, Inc. will participate in the Jefferies London Healthcare Conference on November 19, 2025, highlighting its commitment to innovation and investor relations. The event will feature a live webcast, ensuring accessibility for a broader audience. Novavax aims to showcase its advancements in vaccine technology and strategic growth initiatives.

November 06, 2025 Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights Novavax reported its Q3 2025 financial results, highlighting a strategic focus on partnerships and R&D. Despite a decline in revenue, the company is optimizing collaborations and advancing its vaccine pipeline, positioning itself for future growth.

November 06, 2025 Novavax Inc. Reports Q3 2025 Financial Results: Navigating Challenges Amidst Strategic Partnerships Novavax Inc. reported a Q3 2025 revenue decline to $70.4 million, driven by falling COVID-19 vaccine sales. Despite increased losses, strategic partnerships and a strong product pipeline signal a potential recovery as they restructure operations.

November 04, 2025 Novavax Completes U.S. Marketing Authorization Transfer, Secures $25 Million Milestone Payment On November 4, 2025, Novavax announced the successful U.S. marketing authorization transfer of its COVID-19 vaccine, Nuvaxovid™, to Sanofi, triggering a $25 million milestone payment. This partnership enhances Sanofi's responsibility for marketing and regulatory activities, aiding in the global fight against COVID-19.

October 30, 2025 Novavax Inc. Set to Release Q3 2025 Financial Results Novavax, Inc. will report its Q3 2025 financial results on November 6, 2025. The conference call, scheduled for 8:30 a.m. ET, will provide insights into the company's performance and strategic direction amidst ongoing developments in the biotech sector.

October 22, 2025 Novavax Executes Strategic Site Consolidation to Enhance Financial Efficiency Novavax has successfully executed a site consolidation, securing $60 million in payments and projected savings of $230 million over 11 years. This move aims to streamline operations and enhance financial efficiency while focusing on R&D and technology investments.

October 07, 2025 Novavax Advances Sanofi Partnership with Nuvaxovid® Marketing Authorization Transfer Novavax has successfully transferred the marketing authorization for its COVID-19 vaccine, Nuvaxovid®, to Sanofi in the EU, triggering a $25 million milestone payment. This partnership opens up further financial opportunities and underscores Novavax's commitment to global health through innovative vaccine solutions.

September 30, 2025 Novavax Expands Partnership with Sanofi: A Strategic Move in Pandemic Preparedness Novavax has expanded its partnership with Sanofi to include the use of its Matrix-M adjuvant in developing pandemic influenza vaccines. This collaboration, supported by BARDA funding, aims to enhance pandemic preparedness and vaccine efficacy while offering significant financial benefits to Novavax.

September 04, 2025 Novavax Secures Milestone Payment Following Nuvaxovid® Approval in Japan Novavax has achieved a significant milestone with the approval of its COVID-19 vaccine, Nuvaxovid®, in Japan, leading to a milestone payment and strengthening its market position. This approval allows Nuvaxovid® to be used for initial vaccinations and boosters, positioning it as a key alternative in the vaccine landscape.

September 03, 2025 Novavax to Engage Investors at Cantor Global Healthcare Conference Novavax, Inc. will participate in the Cantor Global Healthcare Conference on September 4, 2025. The fireside chat will provide insights into the company's strategic initiatives and commitment to health innovation, with a webcast available for broader access.

August 27, 2025 Novavax Receives FDA Approval for Nuvaxovid™ 2025-2026 COVID-19 Vaccine Novavax has received FDA approval for its Nuvaxovid vaccine for COVID-19, emphasizing safety and efficacy against the JN.1 variant. The vaccine is crucial for high-risk populations, and its commercialization will be led by Sanofi.

August 21, 2025 Novavax Inc. Announces Convertible Debt Refinancing Novavax, Inc. has announced a refinancing of its convertible debt, issuing $225 million in new Convertible Senior Notes due 2031. This strategic move aims to enhance the company's capital structure and provide better flexibility for future growth initiatives, reflecting strong investor confidence.

August 06, 2025 Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights In Q2 2025, Novavax achieved FDA approval for its COVID-19 vaccine, Nuvaxovid, while transitioning commercial leadership to Sanofi. Despite a revenue decline, the company reported strategic advancements in vaccine development and partnerships.

August 06, 2025 Novavax Inc. Reports Q2 2025 Financial Results: A Mixed Bag Amid Strategic Advancements Novavax Inc. reported a revenue decline in Q2 2025, attributed to reduced licensing and product sales. Despite challenges, the company made strides in strategic partnerships and advanced its vaccine pipeline, positioning itself for future growth.

July 30, 2025 Novavax Inc. Set to Release Second Quarter 2025 Financial Results Novavax, Inc. will announce its second quarter 2025 financial results on August 6, 2025. The conference call will provide crucial insights for investors and stakeholders. A replay will be available for those unable to attend live.

July 24, 2025 Novavax's H5N1 Vaccine Candidate Shows Promising Results in Preclinical Study Novavax's H5N1 vaccine candidate demonstrates robust immune responses in preclinical studies, showing promise for protecting against avian influenza. With strong results from both single and two-dose administrations, the vaccine may enhance public health preparedness against potential outbreaks.

June 11, 2025 Novavax Reports Promising Results for COVID-19-Influenza Combination Vaccine Novavax has announced positive results from its Phase 3 trial for a COVID-19-Influenza Combination vaccine, demonstrating robust immune responses and good safety. This brings hope for effective protection in older adults against dual viral threats.

May 29, 2025 Novavax Inc. Set to Showcase Innovations at Upcoming Investor Conferences Novavax, Inc. is set to participate in two major investor conferences in June 2025, focusing on its vaccine innovations and strategic initiatives. The events will feature a fireside chat and a presentation, with webcasts available for those unable to attend.

May 19, 2025 Novavax Secures FDA Approval for COVID-19 Vaccine: A Major Milestone Novavax's COVID-19 vaccine, Nuvaxovid, has received FDA approval, marking a significant milestone for high-risk populations. The approval prompts a $175 million payment from Sanofi and sets the stage for future commercialization and clinical trials.

May 08, 2025 Novavax Reports Strong First Quarter 2025 Financial Results and Strategic Advancements Novavax, Inc. announced impressive Q1 2025 results, with revenues reaching $667 million, driven by strategic partnerships and innovation in vaccine development. The company is optimistic about future growth, particularly with upcoming BLA approvals and expanded collaborations.

May 08, 2025 Novavax Inc. Reports Strong Q1 2025 Results Amid Strategic Shifts Novavax Inc. reported a remarkable revenue growth to $666.7 million in Q1 2025, attributed to key partnerships and product developments. Despite this success, the company faces a net loss of $518.6 million and ongoing market challenges.

May 07, 2025 Novavax to Showcase Innovations at BofA Securities 2025 Health Care Conference Novavax will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, featuring a fireside chat and investor meetings. The event will highlight Novavax's advancements in vaccine technology and strategic growth plans.

May 05, 2025 Novavax Strengthens Partnership with Takeda Through Enhanced Collaboration Agreement for Nuvaxovid® in Japan Novavax has announced an upgraded partnership with Takeda to enhance the development and commercialization of the COVID-19 vaccine Nuvaxovid® in Japan. The new agreement includes improved financial terms and reflects Novavax's commitment to leveraging innovative technology in the fight against COVID-19.

May 01, 2025 Novavax Inc. Set to Announce Q1 2025 Financial Results Novavax, Inc. will announce its Q1 2025 financial results on May 8, 2025, during a conference call at 8:30 a.m. ET. The call is crucial for stakeholders to assess the company's performance and future strategy in vaccine innovation.

April 29, 2025 Novavax Strengthens Board with Charles Newton Appointment Novavax, Inc. has appointed Charles Newton as an independent director to bolster its Board of Directors. With extensive experience in healthcare investment banking, Newton will drive strategic partnerships and enhance the company's growth strategy, particularly in advancing its innovative vaccine technology.

April 15, 2025 Novavax's COVID-19 Vaccine Shows Promising Results in SHIELD-Utah Study The SHIELD-Utah study highlights Novavax's COVID-19 vaccine as having significantly lower reactogenicity symptoms compared to Pfizer-BioNTech. This finding suggests better tolerability and supports daily activities among recipients, making it a valuable vaccination option.

March 13, 2025 SWOT Analysis of Novavax Inc in 2025 This article provides a comprehensive SWOT analysis of Novavax Inc in 2025, emphasizing its strong vaccine technology and market presence, while addressing financial challenges. It also explores potential growth opportunities and the competitive threats the company faces.

March 11, 2025 Novavax Inc. Announces Strategic Changes to Board of Directors Novavax, Inc. has announced significant changes in its Board of Directors with the appointment of Margaret McGlynn as Chair, succeeding Dr. James Young, and Dr. John Shiver as an independent director. These changes aim to strengthen the company's leadership and strategic focus in the biopharmaceutical sector, particularly in vaccine development.

February 27, 2025 Novavax Inc. Reports 2024 Annual Results: A Year of Challenges and Strategic Shifts Novavax Inc. faced significant challenges in 2024, reporting a revenue drop but making strategic partnerships to enhance its market position. The company’s focus on innovative vaccine solutions and operational adjustments highlights its efforts to navigate a complex health landscape.

February 27, 2025 Novavax Inc. to Showcase Innovations at Upcoming Investor Conferences Novavax Inc. will participate in several key investor conferences in March 2025, showcasing its innovative vaccine technologies and growth strategies. The events will include presentations and investor meetings, with webcasts available for those unable to attend.

February 27, 2025 Novavax Inc. Reports Fourth Quarter and Full Year 2024 Financial Results Novavax, Inc. reported its Q4 and full-year 2024 financial results, highlighting a strategic pivot from COVID-19 vaccine commercialization to enhancing its technology platform. The company is pursuing partnerships and expanding its vaccine pipeline while managing costs effectively, aiming for substantial future growth.

February 20, 2025 Novavax Set to Discuss 2024 Financial Results and Operational Highlights Novavax will host a conference call on February 27, 2025, to discuss its 2024 financial results and operational highlights. Investors can join via dial-in or webcast.

November 12, 2024 Novavax Inc. Reports Q3 2024 Financial Results: A Year of Transition and Growth Novavax Inc. has reported mixed Q3 2024 financial results, with a total revenue decline despite increased COVID-19 vaccine sales. The company is focused on cost reduction and strategic partnerships to enhance its product pipeline and navigate industry challenges.

August 08, 2024 Novavax Inc. Reports Q2 2024 Financial Results: A Turning Point in Vaccine Development Novavax Inc. reported its Q2 2024 results, revealing a net loss reduction and significant revenue from licensing agreements with Sanofi. The company is focusing on cost management and preparing for upcoming vaccine trials and regulatory approvals.

May 10, 2024 Novavax Inc. Reports Q1 2024 Financial Results: A Turning Point in Strategy and Performance In Q1 2024, Novavax Inc. reported a significant financial turnaround, with product sales reaching $82.3 million and a notable decrease in operational expenses. Despite a net income loss, strategic collaborations and ongoing vaccine developments signal a path towards stabilization and growth for the company.

Novavax Set to Discuss 2024 Financial Results and Operational Highlights

Last updated: February 20, 2025 •

Taurigo

1. Upcoming Conference Call Scheduled

On February 20, 2025, Novavax, Inc. (Nasdaq: NVAX), a leading player in the development of protein-based vaccines, announced that it will host a conference call to discuss its fourth quarter and full year financial results for 2024. The call is scheduled for 8:30 a.m. Eastern Time (ET) on February 27, 2025. This event will provide an opportunity for investors and analysts to gain insights into the company’s financial performance and operational developments over the past year.

2. Key Details of the Event

The conference call will be accessible to all interested parties, with several options for participation:

Date: February 27, 2025

Time: 8:30 a.m. U.S. ET

Dial-in Number:

Domestic: (800) 836-8184

International: (+1) (646) 357-8785

Webcast Link: ir.novavax.com/events

Participants can register through a dedicated URL to receive an automated call back, allowing for a seamless connection without operator assistance. It is recommended that attendees join the call at least 10 minutes early to ensure a timely connection.

3. Replay and Additional Access

For those unable to attend the live call, a replay will be available starting at 11:30 a.m. ET on February 27, 2025, and will remain accessible until 11:59 p.m. ET on March 6, 2025. The replay can be accessed via the following:

Dial-in Number for Replay:

Domestic: (888) 660-6345

International: (+1) (646) 517-4150

Passcode: 79349#

Webcast Access: Available at ir.novavax.com/events until March 29, 2025.

4. Novavax's Continued Commitment to Vaccine Innovation

Novavax, headquartered in Gaithersburg, Maryland, is dedicated to promoting health through the discovery and development of innovative vaccines aimed at serious infectious diseases. The company utilizes a unique vaccine platform that combines recombinant protein technologies with its proprietary Matrix-M™ adjuvant to enhance immune responses.

The current portfolio of Novavax includes a COVID-19 vaccine, and the company is actively working on a COVID-19-Influenza Combination vaccine and stand-alone influenza candidates. Additionally, Novavax's adjuvant is integral to the R21/Matrix-M malaria vaccine developed by the University of Oxford and Serum Institute of India, showcasing the company's broad commitment to advancing public health.

As Novavax prepares to share its financial results, investors will be keenly interested in the insights that will be provided regarding the company's ongoing operations and future outlook in the competitive landscape of vaccine development.

Original press release

You may also be interested in: